HRP20100334T1 - Terapeutska humanizirana antitijela protiv cd45-izoforma - Google Patents
Terapeutska humanizirana antitijela protiv cd45-izoforma Download PDFInfo
- Publication number
- HRP20100334T1 HRP20100334T1 HR20100334T HRP20100334T HRP20100334T1 HR P20100334 T1 HRP20100334 T1 HR P20100334T1 HR 20100334 T HR20100334 T HR 20100334T HR P20100334 T HRP20100334 T HR P20100334T HR P20100334 T1 HRP20100334 T1 HR P20100334T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- variable region
- chain
- antibody according
- humanized antibody
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Humanizirano antitijelo, naznačeno time, da ima specifičnost vezanja za oba CD45RO i CD45RB sadržavajući varijabilno područje jakog lanca od SEQ ID NO: 31 ili 32 i varijabilno područje slabog lanca od SEQ ID NO: 7 ili SEQ ID NO: 8. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Humanizirano antitijelo, naznačeno time, da ima specifičnost vezanja za oba CD45RO i CD45RB sadržavajući varijabilno područje jakog lanca od SEQ ID NO: 31 ili 32 i varijabilno područje slabog lanca od SEQ ID NO: 7 ili SEQ ID NO: 8.
2. Humanizirano antitijelo prema zahtjevu 1, naznačeno time, da ima specifičnost vezanja za oba CD45RO i CD45RB sadržavajući:
- varijabilno područje jakog lanca od SEQ ID NO: 31 i varijabilno područje slabog lanca od SEQ ID NO: 7,
- varijabilno područje jakog lanca od SEQ ID NO: 31 i varijabilno područje slabog lanca od SEQ ID NO: 8,
- varijabilno područje jakog lanca od SEQ ID NO: 32 i varijabilno područje slabog lanca od SEQ ID NO: 7, ili
- varijabilno područje jakog lanca od SEQ ID NO: 32 i varijabilno područje slabog lanca od SEQ ID NO: 8.
3. Izolirani polinukleotidi, naznačeni time, da kodiraju za humanizirano antitijelo prema zahtjevu 1 ili 2.
4. Vektor ekspresije, naznačen time, da sadrži polinukleotide iz zahtjeva 3, a taj vektor je sposoban za proizvodnju humaniziranog antitijela kada je spomenuti vektor prisutan u kompatibilnoj stanici domaćina.
5. Izolirana stanica domaćina, naznačena time, da sadrži vektor ekspresije prema zahtjevu 4.
6. Humanizirano antitijelo prema zahtjevima 1 ili 2, naznačeno time, da se koristi kao farmaceutik.
7. Antitijelo prema zahtjevu 6, naznačeno time, da se koristi u liječenju i/ili profilaksi autoimunih oboljenja, odbacivanja transplantata, psorijaze, dermatitisa, upalnih oboljenja crijeva i/ili alergija.
8. Antitijelo prema zahtjevu 7, naznačeno time, da se koristi u liječenju i/ili profilaksi poremećaja stanica domaćina kod transplantacije “graft versus host disease” (GVHD).
9. Antitijelo prema zahtjevu 7, naznačeno time, da se koristi u proizvodnji lijeka za liječenje odbacivanja kod transplantacije žlijezde gušterače.
10. Farmaceutski sastav, naznačen time, da obuhvaća antitijelo iz zahtjeva 1 ili 2 u zajednici s najmanje jednim farmaceutski prihvatljivim nosačem ili razrjeđivačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/666,332 US20050069538A1 (en) | 2003-09-18 | 2003-09-18 | Therapeutic binding molecules |
| GB0414309A GB0414309D0 (en) | 2004-06-25 | 2004-06-25 | Organic compounds |
| PCT/EP2004/010471 WO2005026210A2 (en) | 2003-09-18 | 2004-09-17 | Therapeutic binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100334T1 true HRP20100334T1 (hr) | 2010-07-31 |
Family
ID=34315457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100334T HRP20100334T1 (hr) | 2003-09-18 | 2010-06-10 | Terapeutska humanizirana antitijela protiv cd45-izoforma |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1664122B1 (hr) |
| JP (1) | JP4762142B2 (hr) |
| KR (1) | KR20060079232A (hr) |
| AR (2) | AR045765A1 (hr) |
| AT (1) | ATE461219T1 (hr) |
| AU (1) | AU2004272289B2 (hr) |
| BR (1) | BRPI0414515A (hr) |
| CA (1) | CA2537217A1 (hr) |
| CY (1) | CY1110033T1 (hr) |
| DE (1) | DE602004026081D1 (hr) |
| DK (1) | DK1664122T3 (hr) |
| EC (1) | ECSP066432A (hr) |
| ES (1) | ES2341341T3 (hr) |
| HK (1) | HK1091844A1 (hr) |
| HR (1) | HRP20100334T1 (hr) |
| IL (1) | IL173820A0 (hr) |
| IS (1) | IS8397A (hr) |
| MA (1) | MA28041A1 (hr) |
| MY (1) | MY143963A (hr) |
| NO (1) | NO20061681L (hr) |
| NZ (1) | NZ545605A (hr) |
| PE (1) | PE20060019A1 (hr) |
| PL (1) | PL1664122T3 (hr) |
| PT (1) | PT1664122E (hr) |
| RU (1) | RU2386639C2 (hr) |
| SI (1) | SI1664122T1 (hr) |
| TN (1) | TNSN06087A1 (hr) |
| TW (1) | TW200521231A (hr) |
| WO (1) | WO2005026210A2 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502631A1 (en) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CN105886609B (zh) * | 2015-02-17 | 2020-02-21 | 陈沛隆 | 药物不良反应风险评估方法及其装置 |
| BR112017021536A2 (pt) | 2015-04-06 | 2018-07-03 | Harvard College | composições e métodos para o condicionamento não mieloablativo |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| US20190328901A1 (en) * | 2016-06-17 | 2019-10-31 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| US20230374148A1 (en) | 2020-10-15 | 2023-11-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
| EP4263590A1 (en) | 2020-12-21 | 2023-10-25 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| GB0103389D0 (en) * | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/de active Active
- 2004-09-17 ES ES04765363T patent/ES2341341T3/es active Active
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/ru not_active IP Right Cessation
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/da active
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/ko not_active Application Discontinuation
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/es not_active Application Discontinuation
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/pt not_active Application Discontinuation
- 2004-09-17 SI SI200431411T patent/SI1664122T1/sl unknown
- 2004-09-17 CA CA002537217A patent/CA2537217A1/en not_active Abandoned
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/en active Application Filing
- 2004-09-17 PL PL04765363T patent/PL1664122T3/pl unknown
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/ja not_active Expired - Fee Related
- 2004-09-17 EP EP04765363A patent/EP1664122B1/en active Active
- 2004-09-17 AT AT04765363T patent/ATE461219T1/de active
- 2004-09-17 TW TW093128255A patent/TW200521231A/zh unknown
- 2004-09-17 AR ARP040103362A patent/AR045765A1/es active IP Right Grant
- 2004-09-17 PT PT04765363T patent/PT1664122E/pt unknown
-
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/fr unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/es unknown
- 2006-04-03 IS IS8397A patent/IS8397A/is unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/no not_active Application Discontinuation
- 2006-11-09 HK HK06112334.4A patent/HK1091844A1/xx unknown
-
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/el unknown
- 2010-06-10 HR HR20100334T patent/HRP20100334T1/hr unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100334T1 (hr) | Terapeutska humanizirana antitijela protiv cd45-izoforma | |
| CN102775493B (zh) | IL-1β结合抗体及其片段 | |
| HRP20171084T1 (hr) | Tihe fc-varijante protutijela anti-cd40 | |
| WO2005054273A3 (en) | Humanized antibodies against vascular endothelial growth factor | |
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| WO2006002177A3 (en) | Interferon alpha receptor 1 antibodies and their uses | |
| AR035539A1 (es) | Moleculas de enlace capaces de enlazarse a isoformas cd45, polinucleotidos codificantes, un vector de expresion, un sistema de expresion, una celula huesped, el uso de dichas moleculas para la produccion de un medicamento y composiciones farmaceuticas. | |
| UA101603C2 (ru) | Гуманизированное антитело к фактору d и его применение | |
| RU2011110169A (ru) | Антитела против ccr2 | |
| WO2005110474A3 (en) | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| JP2018521691A5 (hr) | ||
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| ATE426615T1 (de) | Fur ein dem tumor-nekrose-faktor ahnlichen, apoptose-induzierenden ligandenrezeptor selektiven antikírper und dessen anwendungen | |
| UA93027C2 (ru) | Мутантное антитело, которое специфически связывается с cd40 | |
| WO2003048327A3 (en) | Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection | |
| JP2017518258A5 (hr) | ||
| Rangel-Santos et al. | Immunosuppresive role of principal toxin (crotoxin) of Crotalus durissus terrificus venom | |
| CN103298488A (zh) | 与α2整联蛋白结合的肽或肽复合物以及涉及所述肽或肽复合物的方法和用途 | |
| JP2021155456A (ja) | 黄色ブドウ球菌ロイコシジンの細胞毒性に関与する細胞因子：新規治療標的 | |
| JP2022141959A5 (hr) | ||
| Hakimi et al. | Development of Zenapax®: a humanized anti-Tac antibody | |
| CL2023002393A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| MX2022002418A (es) | Composiciones y metodos de tratamiento de enfermedades vasculares. | |
| CN105263962A (zh) | 抗体及用于治疗与雌激素受体相关疾病的方法 |